Successful treatment of IBL-like T-cell lymphoma with cyclosporin A: two case reports with special reference to serum cytokine levels.

Abstract

The prognosis of immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma is grave, and its effective treatments have not been established. We applied oral cyclosporin A (CsA) treatment to two cases of IBL-like T-cell lymphoma, and succeeded in achieving complete remissions. CsA is known to have a suppressive effect on the immune system, most notably T-cells, but it also has a direct cytotoxic/apoptosis-inducing effect on lymphocytes. Its combined effects on neoplastic T-cells might have played an important role in achieving remission. In both cases, serum levels of interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-alpha) were elevated and decreased or returned to normal after achieving remissions. Considering that both cytokines represent monokines, it seems that a macrophage system is also involved in the pathogenesis of this disorder. Our two cases indicate that administration of CsA may be an effective therapy for IBL-like T-cell lymphoma.

• Authors: N Takemori, J Kodaira, T Sato, H Sakurai, N Akakura, S Kimura, M Katagiri
• Journal: Human cell (Hum Cell) Vol. 13 Issue 1 Pg. 35-42 (Mar 2000) ISSN: 0914-7470 [Print] Japan
• PMID: 10937345 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cytokines
• Immunosuppressive Agents
• Cyclosporine

Topics

• Administration, Oral
• Aged
• Cyclosporine (administration & dosage)
• Cytokines (blood)
• Female
• Humans
• Immunoblastic Lymphadenopathy (drug therapy, immunology)
• Immunosuppressive Agents (administration & dosage)
• Lymphoma, T-Cell (drug therapy, immunology)
• Male
• Middle Aged
• Remission Induction
• Treatment Outcome